Genetic and Functional Sequence Variants of the SIRT3 Gene Promoter in Myocardial Infarction

Xiaoyun Yin1, Shuchao Pang2, Jian Huang2, Yinghua Cui3, Bo Yan2,4*

1 Department of Medicine, Shandong University School of Medicine, Jinan, Shandong, China, 2 Shandong Provincial Key Laboratory of Cardiac Disease Diagnosis and Treatment, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China, 3 Division of Cardiology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China, 4 Shandong Provincial Sino-US Cooperation Research Center for Translational Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China

* yanbo@mail.jnmc.edu.cn; yanbmd@gmail.com

Abstract

Coronary artery disease (CAD), including myocardial infarction (MI), is a common complex disease that is caused by atherosclerosis. Although a large number of genetic variants have been associated with CAD, only 10% of CAD cases could be explained. It has been proposed that low frequent and rare genetic variants may be main causes for CAD. SIRT3, a mitochondrial deacetylase, plays important roles in mitochondrial function and metabolism. Lack of SIRT3 in experimental animal leads to several age-related diseases, including cardiovascular diseases. Therefore, SIRT3 gene variants may contribute to the MI development. In this study, SIRT3 gene promoter was genetically and functionally analyzed in large cohorts of MI patients (n = 319) and ethnic-matched controls (n = 322). Total twenty-three DNA sequence variants (DSVs) were identified, including 10 single-nucleotide polymorphisms (SNPs). Six novel heterozygous DSVs, g.237307A>G, g.237270G>A, g.237023_25del, g.236653C>A, g.236628G>C, g.236557T>C, and two SNPs g.237030C>T (rs12293349) and g.237022C>G (rs369344513), were identified in nine MI patients, but in none of controls. Three SNPs, g.236473C>T (rs11246029), g.236380_81ins (rs71019893) and g.236370C>G (rs185277566), were more significantly frequent in MI patients than controls (P<0.05). These DSVs and SNPs, except g.236557T>C, significantly decreased the transcriptional activity of the SIRT3 gene promoter in cultured HEK-293 cells and H9c2 cells. Therefore, these DSVs identified in MI patients may change SIRT3 level by affecting the transcriptional activity of SIRT3 gene promoter, contributing to the MI development as a risk factor.

Introduction

Coronary artery disease (CAD) is a common complex disease, which is a leading cause of human death around the world. Myocardial infarction (MI) is a specific type of CAD.
Atherosclerosis, an inflammatory and metabolic disease, is the main cause for CAD and MI. Known risk factors include hypertension, smoking, diabetes, hyperlipoproteinemia and hypercholesterolemia. Though genome-wide association studies have identified more than 50 genetic loci to CAD, these genetic variants account for only 10% of cases [1–3]. To date, genetic causes and underlying molecular mechanisms for CAD remain largely unclear. It has been hypothesized that low frequency and rare variants with large effects may account for some of the missing heritability for CAD. Recently, epigenetic factors have been suggested to contribute to aging and age-associated diseases [4].

Sirtuins (SIRTs), a family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases, have been involved in a wide range of cellular processes, including aging, calorie restriction, stress resistance, apoptosis, inflammation, mitochondrial function and circadian clock. Dysfunctional SIRTs have been implicated in a variety of age-related diseases, including cardiovascular diseases [5,6]. Seven SIRTs, SIRT1-7, have been identified in mammals. SIRT3 is localized in mitochondria and has been extensively studied. Increased expression of SIRT3 gene has been associated with extended lifespan of humans [7–9]. SIRT3 regulates the enzymes involving in the respiratory chain, ATP production, fatty acid oxidation, tricarboxylic acid cycle and urea cycle, and reduces levels of reactive oxygen species (ROS) and oxidative stress [10–12]. Tissue-specific SIRT3 deletion studies suggest its non-tissue-autonomous roles [13]. Therefore, SIRT3 plays an important role in regulating mitochondrial function and metabolism. Lack of SIRT3 in experimental animal leads to several age-related diseases, such as cancer, metabolic syndrome, cardiovascular disease, and neurodegenerative diseases [14].

SIRT3 has been demonstrated to protect cardiomyocytes from aging, oxidative stress and dysregulated metabolism, and suppresses cardiac hypertrophy [15,16]. In cultured cardiomyocytes, SIRT3 inhibits myocardial reperfusion injury and reduces oxidative stress-induced apoptosis [17,18]. SIRT3 knockdown increases the susceptibility of cultured cardiomyocytes and adult hearts to ischemia-reperfusion injury [19]. In SIRT3-knockout mice, ROS levels are increased in the cardiomyocytes, indicating that SIRT3 prevents cellular ROS accumulation in the heart [20]. Mitochondrial permeability is also increased in the heart, leading to mitochondrial dysfunction [21]. SIRT3 is necessary for bone marrow cell-mediated cardiac repair in post-myocardial infarction [22]. In human endothelial cells, SIRT3 mediates the cellular response to hypoxia and protects the cells from high glucose-induced cytotoxicity [23,24]. In humans and animals, SIRT3 has been shown to regulate lipid metabolism and reduce lipid accumulation in diverse tissues, including heart [25–27]. SIRT3 has recently been reported to be involved in inflammation as well as platelet aging and thrombosis [28,29]. In addition, overexpressed SIRT3 enhances autophagy, which plays an important role in the development of cardiovascular diseases, including atherosclerosis, cardiac ischemia/reperfusion, cardiomyopathy and heart failure [30–32]. Therefore, SIRT3 may be involved in development of cardiovascular diseases through pathways of metabolism, inflammation and others.

SIRT3 gene expression has been studied and reported in several human diseases. SIRT3 gene expression is increased in hepatocellular carcinoma cells and human embryonic kidney cells (HEK-293) under hyperglycemic conditions [33]. Decreased SIRT3 expression has been reported in the patients with metabolic syndrome, non-alcoholic fatty liver disease, pulmonary arterial hypertension and type 2 diabetes [34–37]. Downregulated and upregulated SIRT3 gene expression has also been observed in different cancer tissues, depending on the cell and cancer types [38,39]. However, molecular mechanisms by which SIRT3 gene expression is changed have not been reported. We speculated that the DNA sequence variants (DSVs) within the regulatory regions of the SIRT3 gene may account for the changed SIRT3 gene expression. In this study, we genetically and functionally analyzed the promoter region of the SIRT3 gene in large cohorts of MI patients and healthy controls.
Materials and Methods

Patients and controls

All MI patients (n = 319, male 236, female 89, age range from 33 to 90 years, median age 60.03 years) were recruited between July, 2012 to November, 2014, from Cardiac Care Unit, Division of Cardiology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China. All MI patients were diagnosed according to international guideline criteria: ischemic symptoms, ECG changes (ST-segment elevation or depression), typical rise of biochemical markers of myocardial necrosis (troponin or creatine kinase-MB), or coronary angioplasty. Patients with valvular heart disease, cardiomyopathy, myocarditis, or postrevascularization of the coronary arteries were excluded from this study. Ethnic-matched healthy controls (n = 322, male 172, female 150, age range from 21 to 82 years, median age 48.97 years) were recruited from the same hospital. Controls with familial MI history were excluded. In this study, 342 MI patients and 346 controls were initially recruited. Since DNA sequencing for some samples were failed, total 319 MI patients and 322 controls were finally included. The research was carried out according to the principles of the Declaration of Helsinki. This study was approved by the Human Ethic Committee of Affiliated Hospital of Jining Medical University. Written informed consents were obtained.

DNA Sequence analysis

Peripheral leukocytes were isolated and genomic DNAs were extracted. SIRT3 gene promoter (1200bp upstream to the transcription start site) was sequenced and analyzed. Two overlapped DNA fragments, 764bp (-1200bp~-437bp) and 678bp (-498bp~+180bp), were generated by PCR. PCR primers were designed based on genomic sequence of the human SIRT3 gene (NCBI, NC_000011.10), which were shown in Table 1. PCR products were bi-directionally sequenced with Applied Biosystems 3500xL genetic analyzer. The DNA sequences were then aligned with the wild type sequence of the SIRT3 gene promoter.

Functional analysis of the DSVs by dual-luciferase reporter assays

Expression vectors were constructed by subcloning wild type and variant SIRT3 gene promoters into luciferase reporter vector (pGL3-basic) and dual-luciferase activities were examined. Briefly, DNA fragments of wild type and variant SIRT3 gene promoters (1179bp, from -999bp to +180bp to the transcription start site) were generated by PCR and then subcloned into KpnI and Hind III sites of pGL3-basic to generate expression vectors. The PCR primers with KpnI or HindIII sites were shown in Table 1. Designated expression vectors were transiently transfected into human embryonic kidney cells (HEK-293, from ATCC, CRL-1573) or rat cardiomyocyte line cells (H9c2, from ATCC, CRL-1446). After 48 hours, the luciferases activities of the transfected cells were measured using dual-luciferase reporter assay system on a Promega Glomax 20/20 luminometer. Expression vector pRL-TK expressing renilla luciferase was used as an internal control for transfection. Empty vector pGL3-basic was used as a negative control. The transcriptional activities of the SIRT3 gene promoter were represented as ratios of luciferase activities over renilla luciferase activities. All the experiments were repeated three times independently, in triplicate.

Statistical analysis

The quantitative data were represented as mean ± SEM and compared by a standard Student’s t-test. DSV frequencies in MI patients and controls were analyzed and compared with SPSS v13.0. P<0.05 was considered statistically significant.
Results

Identified DSVs of the SIRT3 gene promoter

In this population, total 23 DSVs, including 10 SNPs, were identified. The locations and frequencies of the DSVs and SNPs were shown in Fig 1 and Table 2. Five novel heterozygous DSVs (g.237307A>G, g.237270G>A, g.236653C>A, g.236628G>C, g.236557T>C), one novel heterozygous deletion DSV (g.237023_25del) and two SNPs [g.237030C>T (rs12293349) and g.237022C>G (rs369344513)] were identified in 9 MI patients, but in none of controls. Chromatograms of these novel DSVs were shown in Fig 2. Three SNPs, g.236473C>T (rs11246029), g.236380_81ins (rs71019893) and g.236370C>G (rs185277566) were more significantly frequent in MI patients than controls (P<0.05). More interestingly, SNPs g.236380_81ins (rs71019893) and g.236370C>G (rs185277566) were closely linked together with the same frequencies.

Six novel heterozygous DSVs, g.236956G>T, g.236878_79ins, g.236634C>T, g.236460T>C and g.236458G>A, were only found in two controls. Chromatograms of these novel DSVs were shown in Fig 3. The rest five SNPs [g.237312T>C (rs3817629), g.237209G>A (rs56312618), g.237087A>G (rs1045288), g.236871T>C (rs2272563) and g.236775delC (rs369178836)] and one deletion DSV (g.236385_86ins), were found in both VSD patients and controls with similar frequencies (P>0.05).

Table 1. PCR primers for the SIRT3 gene promoter.

| PCR primers | Sequences          | Location | Position | Products |
|-------------|--------------------|----------|----------|----------|
| Sequencing  |                    |          |          |          |
| SIRT3-F1    | 5'-AAGCACGAATCACCACACAT-3' | 237562   | -1200    | 764bp    |
| SIRT3-R1    | 5'-CCCCACACCTGGGACGGCT-3' | 236799   | -437     |          |
| SIRT3-F2    | 5'-CGGCGTTTGAGCCACCTTTC-3' | 236860   | -498     | 678bp    |
| SIRT3-R2    | 5'-CGGCACTCAGTGCTCCCTT-3' | 236183   | +180     |          |
| Functioning |                    |          |          |          |
| SIRT3-F     | 5'-KpnI-CTTGAGCCCTGGGTATC-3' | 237361   | -999     | 1179bp   |
| SIRT3-R     | 5'-HindIII-GGCGAGTCAAGGAGTCT-3' | 236183   | +180     |          |

PCR primers are designed based on the genomic DNA sequence of the SIRT3 gene (NC_000011.10). The transcription start site (TSS) is at the position of 236362 (+1).

doi:10.1371/journal.pone.0153815.t001

*Fig 1. Locations of the DSVs within the SIRT3 gene promoter in MI patients and controls. The numbers represents the genomic DNA sequences of the human SIRT3 gene (Genebank accession number NC_000011.10). The transcription start site is at the position of 236362 in the first exon.*

doi:10.1371/journal.pone.0153815.g001
Putative binding sites for transcription factors affected by DSVs

The SIRT3 gene promoter was analyzed with JASPAR program (http://jaspar.genereg.net/). The DSVs identified in MI patients may abolish, create and modify the putative binding sites for transcription factors. For example, the DSV g.237307A>G may abolish the binding sites for SPIB [Spi-B transcription factor (Spi-1/PU.1 related)] and myeloid zinc finger 1, and create the binding sites for estrogen-related receptor beta and nuclear receptor subfamily 4 group A.
member 2. The DSV g.237270G>A may abolish the binding sites for hairy/enhancer-of-split related with YRPW motif protein 2 and the dimer between hypoxia-inducible factor 1-alpha and aryl hydrocarbon receptor nuclear translocator, and create the binding sites for doublesex and Mab-3 related transcription factor 3, HLTF (helicase-like transcription factor) and MEIS1. The SNP g.237030C>T (rs12293349) may create the binding sites for zinc finger and BTB domain containing 7B, insulinoma-associated 1, MEIS1 and SOX10 [SRY (sex determining region Y) box 10]. The DSV g.237023_25del may abolish the binding site for SPIB. The SNP g.237022C>G (rs369344513) may abolish the binding site for SPIB and create the binding site for FOXD2 (forkhead box factor D2). The DSV g.236653C>A may abolish the binding site for SOX10 and create the binding sites for caudal-related homeobox transcription factor 1, homeobox factors, motor neuron and pancreas homeobox 1, NKX6-1 (NK6 transcription factor related, locus 1), NKX6-2 and NK-related factor NOTO. The DSV g.236628G>C may abolish the binding sites for E74-Like factor 5, Ets-variant gene 5, chorion-specific transcription factor GCMb, neurogenic differentiation factor 2, SAM pointed domain containing ETS transcription factor and THAP domain-containing protein 1. The DSV g.236557T>C may abolish the binding sites for FOS transcription factor L1, transcription factor JUND and MEIS1 and create a binding site for HLTF. The SNP g.236473C>T (rs11246029) may abolish the binding sites for zinc finger protein 263, SP4 (specificity protein 4), KLF14 (Kruppel-like factor 14) and SP8, and create a binding site for E2F transcription factor 6. The SNP g.236380_81ins
(rs71019893) may abolish the binding sites for SP1, SP2, KLF5 and KLF16, and create binding sites for TFAP2A (transcription factor AP-2 alpha), TFAP2B, TFAP2C, ZIC1 (zinc finger transcription factor 1) and ZIC4. The SNP g.236370C>G (rs185277566) may abolish the binding sites for early growth response protein 1, KLF16, SP1, SP2 and SP3.

DSVs Effects on transcriptional activity of SIRT3 gene promoter

Wild type and variant SIRT3 gene promoters were cloned into luciferase reporter vector (pGL3-basic) to generate expression constructs. After transfected into cultured cells, rat cardiomyocyte cells (H9c2) and human embryonic-kidney cells (HEK-293), dual-luciferase activities were assayed to examine the transcriptional activities of the SIRT3 gene promoter. In H9c2 cells, the DSVs only identified in MI patients or the DSVs found in MI patients with higher frequencies, g.236307A>G, g.236730G>A+g.236370C>G, g.237030C>T, g.236557T>C, g.236460T>C and g.236458G>A, significantly repressed the transcriptional activities of the SIRT3 gene promoter to different extents (P<0.05, Fig 4). However, the DSV g.236557T>C, which was identified in a MI patient, did not significantly alter the transcriptional activity of the SIRT3 gene promoter (P>0.05). As expected, the DSVs only identified in controls or the DSVs found in MI patients and controls with similar frequencies, g.238912T>A, g.236364G>T, g.236775ins (rs369178836), g.236634C>T+g.236634C>T and g.236460T>C, did not significantly change the transcriptional activity of the SIRT3 gene promoter (P>0.05).

We further examined effects of the DSVs on the transcriptional activities of the SIRT3 gene promoter in HEK-293 cells. As shown in Fig 5, all the DSVs only identified in MI patients or
Fig 4. Relative transcriptional activities of wild type and variant SIRT3 gene promoters in H9c2 cells. Wild type and variant SIRT3 gene promoters were cloned into reporter gene vector pGL3 and transfected into H9c2 cells. Dual-luciferase activities were assayed and relative activities of SIRT3 gene promers were obtained. Transcriptional activity of the wild type SIRT3 gene promoter was designed as 100%. Lanes 1, pGL3-WT; 2, pGL3 control; 3, pGL3-g.237312T>C (rs3817629); 4, pGL3-g.237307A>G; 5, pGL3-g.237270G>A + g.236370C>G + g.236380_81ins; 6, pGL3-g.237030C>T (rs12293349); 7, pGL3-g.237023_25del; 8, pGL3-g.237022C>G (rs369344513); 9, pGL3-g.236956G>T; 10, pGL3-g.236878_79ins; 11, pGL3-g.236775del (rs369178836); 12, pGL3-g.236653C>A + g.236473C>T; 13, pGL3-g.236634C>T; 14, pGL3-g.236628G>C; 15, pGL3-g.236583A>C; 16, pGL3-g.236557T>C; 17, pGL3-g.236460T>C. *, P<0.05; **, P<0.01.

doi:10.1371/journal.pone.0153815.g004

Fig 5. Relative transcriptional activities of wild type and variant SIRT3 gene promoters in HEK-293 cells. Expression constructs for wild type and variant SIRT3 gene promoters were transfected into HEK-293 cells and dual-luciferase activities were measured. Transcriptional activity of the wild type SIRT3 gene promoter was designed as 100%. Lanes 1, pGL3-WT; 2, pGL3 control; 3, pGL3-g.237312T>C (rs3817629); 4, pGL3-g.237307A>G; 5, pGL3-g.237270G>A + g.236370C>G + g.236380_81ins; 6, pGL3-g.237030C>T (rs12293349); 7, pGL3-g.237023_25del; 8, pGL3-g.237022C>G (rs369344513); 9, pGL3-g.236653C>A + g.236473C>T; 10, pGL3-g.236628G>C; 11, pGL3-g.236557T>C. **, P<0.01.

doi:10.1371/journal.pone.0153815.g005
the DSVs found in MI patients with higher frequencies, g.237307A>G, g.237270G>A+-g.236370C>G, g.236380_81ins, g.237030C>T (rs12293349), g.237023_25del, g.237022C>G (rs369344513), g.236653C>A+g.236473C>T, g.236628G>C and g.236557T>C, significantly repressed the transcriptional activities of the SIRT3 gene promoter (P<0.05). The DSV g.236557T>C, which did not change the transcriptional activity of the SIRT3 gene promoter in H9c2 cells, significantly repressed the transcriptional activity of the SIRT3 gene promoter in HEK-293 cells, suggesting that the DSV may alter the binding site for a tissue-specific transcription factor.

Discussion

To date, few studies have associated the SIRT3 gene with human diseases. A SNP rs11246020 (NC_000011.10:g.233067C>T) in the human SIRT3 gene, a nonsynonymous point mutation (V208I) which reduces its enzymatic activity, may enhance the susceptibility to metabolic syndrome [35]. A SNP rs11555236 (NC_000011.10:g.233212C>A) in intron 5 of the SIRT3 gene, which increases expression of SIRT3 gene, has been associated with extended lifespan of humans [7]. In this study, we have identified a total of 23 DSVs within the promoter of the human SIRT3 gene. Six novel heterozygous DSVs and two SNPs were identified in MI patients, but in none of controls (Table 2 and Fig 2). Three SNPs were found in MI patients with significantly higher frequencies compared to controls (Table 2). These DSVs and SNPs, except the DSV g.236557T>C, significantly decreased the transcriptional activities of the SIRT3 gene promoter in both H9c2 cells and HEK-293 cells (Figs 4 and 5). Therefore, these SIRT3 gene promoter DSVs may reduce SIRT3 levels, contributing to the MI development as risk factors.

The human SIRT3 gene is localized to the chromosome 11p15.5, and encodes an NAD-dependent mitochondrial deacetylase of 399-amino acids containing an N-terminal mitochondrial targeting signal and a central catalytic domain [40–42]. SIRT3 gene is expressed in a variety of tissues with higher expression in adipose tissue, brain and heart in embryos and adults (NCBI Unigene EST Profile Viewer), indicating the tissue-specific regulation of the SIRT3 gene expression. The human SIRT3 gene promoter contains high GC contents and lacks the TATA box sequence and there are binding sites for activator protein 1 (AP1), GATA-binding factor, nuclear Factor κB (NF-κB) and transcription factor ZF5, as well as multiple specificity protein 1 (SP1) binding sites [43]. Nuclear respiratory factor 2, a transcription factor that regulates mitochondrial genes, binds to the promoter of SIRT3 gene and induces its expression [44]. In this study, the DSVs reduced the SIRT3 promoter transcriptional activity in HEK-293 cells and H9c2 cells to different extents, which may be due to the tissue-specificity of the SIRT3 gene expression and related transcription factors. Therefore, expression of the human SIRT3 gene may be manipulated for therapeutic purposes.

A series of downstream substrates of SIRT3, as well as histone, have been identified. SIRT3 deacetylates and activates several enzymes that are critical in maintaining cellular ROS levels and promote resistance to oxidative stress, including superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) [12,45–49]. In experimental animals, SIRT3 deacetylates FOXO3a, a transcription factor that upregulates SOD2 and catalase, and decreases ROS levels [20]. Increased ROS levels and oxidative stress have been demonstrated to contribute to the atherogenesis [50,51]. In human endothelial cells, SIRT3 deacetylates and stabilizes FOXO3 to protect mitochondria against oxidative stress, and activates mitochondrial aldehyde dehydrogenase 2, a key enzyme to remove reactive aldehydes [24,52–54]. In the mitochondria, SIRT3 deacetylates acetyl-CoA synthase 2, 3-hydroxy-3-methylglutaryl CoA synthase 2,
mitochondrial fusion protein optic atrophy 1 and regulatory component of the mitochondrial permeability transition pore, cyclophilin D [21,35,54]. SIRT3 has been shown to regulate long-chain acyl-CoA dehydrogenase, a key mitochondrial fatty acid oxidation enzyme [55]. SIRT3 regulates fatty acid oxidation through heat shock protein 10 [56]. In human diploid fibroblasts, SIRT3 overexpression antagonizes high glucose-induced cellular senescence via the SIRT3-FOXO1 signaling pathway [57]. A recent study has shown that SIRT3 targets human very long-chain acyl-CoA dehydrogenase, a key fatty acid oxidation enzyme [58]. Therefore, decreased SIRT3 levels may contribute to MI development by: 1) affecting lipid metabolism, inflammation and other pathways, initiating the atherosclerosis; and 2) interfering with fatty acid oxidation, ROS generation and mitochondrial functions, leading to death of cardiomyocytes. Exact molecular mechanisms need further investigated and elucidated.

Conclusions

In this study, we genetically and functionally analyzed the SIRT3 gene promoter. The DSVs and SNPs of the SIRT3 gene promoter identified in MI patients may alter transcriptional activity of SIRT3 gene promoter and change SIRT3 level, contributing to the MI development as a risk factor. The investigation into the molecular mechanisms by which SIRT3 gene promoter activity are affected are being conducted in our laboratory. Therefore, our findings may provide a genetic basis for further translational and clinical studies for MI patients.

Author Contributions

Conceived and designed the experiments: XY BY. Performed the experiments: XY SP JH. Analyzed the data: XY SP YC BY. Contributed reagents/materials/analysis tools: YC. Wrote the paper: XY SP BY.

References

1. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012; 148: 1242–57. doi: 10.1016/j.cell.2012.03.001 PMID: 22424232
2. Ozaki K, Tanaka T. Molecular genetics of coronary artery disease. J Hum Genet. 2016; 61: 71–7. doi: 10.1038/jhg.2015.70 PMID: 26134515
3. Roberts R. Genetics of coronary artery disease. Circ Res. 2014; 114: 1890–903. doi: 10.1161/CIRCRESAHA.114.302692 PMID: 24902973
4. Ben-Avraham D. Epigenetics of aging. Adv Exp Med Biol. 2014; 30: 271–86. doi: 10.1007/978-1-4939-2404-2_9 PMID: 25916592
5. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012; 11: 443–61. doi: 10.1038/nrd3738 PMID: 22653216
6. Giblin W, Skinner ME, Lombard DB. Sirtuins: guardians of mammalian healthspan. Trends Genet. 2014; 30: 271–86. doi: 10.1016/j.tig.2014.04.007 PMID: 24877878
7. Albani D, Ateri E, Mazzuco S, Ghilardi A, Rodoliosi S, Biella G, et al. Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study “Treviso Longeva (TRELONG)” Age (Dordr). 2014; 36: 469–78.
8. Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De Rango F, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics. 2005; 85: 258–63. PMID: 15676284
9. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003; 38: 1065–70. PMID: 14580659
10. Bause AS, Haigis MC. SIRT3 regulation of mitochondrial oxidative stress. Exp Gerontol. 2013; 48: 634–9. doi: 10.1016/j.exger.2012.08.007 PMID: 22964489
Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010; 464: 121–5. doi: 10.1038/nature08778 PMID: 20203611

Merskamer PI, Liu Y, He W, Hirschey MD, Chen D, Verdin E. The sirtuins, oxidative stress and aging: an emerging link. Aging (Albany NY). 2013; 5: 144–50.

Lombard DB, Zwaans BM. SIRT3: as simple as it seems? Gerontology. 2014; 60: 56–64. doi: 10.1159/000354382 PMID: 24192814

McDonnell E, Peterson BS, Bomze HM, Hirschey MD. SIRT3 regulates progression and development of diseases of aging. Trends Endocrinol Metab. 2015; 26: 486–92. doi: 10.1016/j.tem.2015.06.001 PMID: 26138757

Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol. 2015; 309: H1375–89. doi: 10.1152/ajpheart.00053.2015 PMID: 26232232

Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015; 36: 3404–12. doi: 10.1093/eurheartj/ehv290 PMID: 26128899

Bochaton T, Crola-Da-Silva C, Pilott B, Villedieu C, Ferreras L, Alam MR, et al. Inhibition of myocardial reperfusion injury by ischemic preconditioning requires sirtuin 3-mediated deacetylation of cyclophilin D. J Mol Cell Cardiol. 2015; 84: 61–9. doi: 10.1016/j.yjmcc.2015.03.017 PMID: 25871830

Chen CJ, Fu YC, Yu W, Wang W. SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-κB. Biochem Biophys Res Commun. 2013; 430: 798–803. doi: 10.1016/j.bbrc.2012.11.066 PMID: 23201401

Porter GA, Urciuoli WR, Brookes PS, Nadtochiy SM. SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol. 2014; 306: H1602–9. doi: 10.1152/ajpheart.00027.2014 PMID: 24748594

Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009; 119: 2758–71. doi: 10.1172/JCI39162 PMID: 19652361

Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010; 2: 914–23.

Zeng H, Li L, Chen JX. Loss of Sirt3 limits bone marrow cell-mediated angiogenesis and cardiac repair in post-myocardial infarction. PLoS One. 2014; 9: e107011. doi: 10.1371/journal.pone.0107011 PMID: 25192254

Liu G, Cao M, Xu Y, Li Y. SIRT3 protects endothelial cells from high glucose-induced cytotoxicity. Int J Clin Exp Pathol. 2015; 8: 353–60. PMID: 25755722

Tseng AH, Wu LH, Shieh SS, Wang DL. SIRT3 interactions with FOXO3 acetylation, phosphorylation and ubiquitinylatation mediate endothelial cell responses to hypoxia. Biochem J. 2014; 464: 157–68. doi: 10.1042/BJ20140213 PMID: 25162939

de Moura MB, Uppala R, Zhang Y, Van Houten B, Goetzman ES. Overexpression of mitochondrial sirtuins alters glycolysis and mitochondrial function in HEK293 cells. PLoS One. 2014; 9: e106028. doi: 10.1371/journal.pone.0106028 PMID: 25165814

Choudhury M, Jonscher KR, Friedman JE. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat. Aging (Albany NY). 2011; 3: 175–8.

Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis. 2010; 11: 55–62. doi: 10.1111/j.1751-2980.2009.00416.x PMID: 20132432

Barger JL, Anderson RM, Newton MA, da Silva C, Vann JA, Pugh TD, et al. A conserved transcriptional signature of delayed aging and reduced disease vulnerability is partially mediated by SIRT3. PLoS One. 2015; 10: e0120738. doi: 10.1371/journal.pone.0120738 PMID: 25830335

Kumari S, Chaurasia SN, Nayak MK, Mallick RL, Dash D. Sirtuin Inhibition Induces Apoptosis-like Changes in Platelets and Thrombocytopenia. J Biol Chem. 2015; 290: 12290–9. doi: 10.1074/jbc.M114.615948 PMID: 25829495

Liang Q, Benavides GA, Vassilopoulos A, Gius D, Darley-Usmar V, Zhang J. Bioenergetic and autophagic control by Sirt3 in response to nutrient deprivation in mouse embryonic fibroblasts. Biochem J. 2013; 454: 249–57. doi: 10.1042/BJ20130414 PMID: 23767918

Luo X, Yang Z, Zheng S, Cao Y, Wu Y. Sirt3 activation attenuated oxidized low-density lipoprotein-induced human umbilical vein endothelial cells' apoptosis by sustaining autophagy. Cell Biol Int. 2014; doi: 10.1002/cbin.10291 [Epub ahead of print]

Mei Y, Thompson MD, Cohen RA, Tong X. Autophagy and oxidative stress in cardiovascular diseases. Biochim Biophys Acta. 2015; 1852: 243–51. doi: 10.1016/j.bbadis.2014.05.005 PMID: 24834848
33. Gounden S, Phulukdaree A, Moodley D, Chuturgoon A. Increased SIRT3 Expression and Antioxidant Defense under Hyperglycemic Conditions in HepG2 Cells. Metab Syndr Relat Disord. 2015; 13: 255–63. PMID: 26042459

34. Caton PW, Richardson SJ, Kieswich J, Bugiani M, Holland ML, Marchetti P, et al. Sirtuin 3 regulates mouse pancreatic beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic patients. Diabetologia. 2013; 56: 1068–77. doi: 10.1007/s00125-013-2851-y PMID: 23397292

35. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Auouzerat B, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011; 44: 177–90. doi: 10.1016/j.molcel.2011.07.019 PMID: 21856199

36. Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014; 20: 827–39. doi: 10.1016/j.cmet.2014.08.011 PMID: 25284742

37. Wu T, Liu YH, Fu YC, Liu XM, Zhou XH. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients. Ann Clin Lab Sci. 2014; 44: 410–8. PMID: 25361925

38. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011; 1816: 180–8. doi: 10.1016/j.bbamcr.2011.04.004 PMID: 21586315

39. Chen Y, Fu LL, Wen X, Wang XY, Liu J, Cheng Y, et al. Sirtuin-3 (SIRT3), a therapeutic target with anti-diabetic effects. Biochim Biophys Acta. 2011; 1816: 80–8. doi: 10.1016/j.bbamcr.2011.04.004 PMID: 21586315

40. Sato T, Kominami E, Sato T, et al. SIRT3 is a new homeostatic regulator of mitochondrial function in the heart. J Mol Cell Cardiol. 2013; 59: 110–20. doi: 10.1016/j.yjmcc.2013.04.010 PMID: 23646539

41. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A. 2002; 99: 273–9. PMID: 12058777

42. Bellizzi D, Dato S, Cavalcante P, Covello G, Di Cianni F, Passarino G, et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics. 2007; 89: 143–50. PMID: 17059877

43. Satterstrom FK, Swindell WR, Laurent G, Vyas S, Bulyk ML, Haigis MC. Nuclear respiratory factor 2 induces SIRT3 expression. Aging Cell. 2015; 14: 818–25. doi: 10.1111/acel.12360 PMID: 26109058

44. Shen J, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, et al. Tumor suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011; 12: 534–41. doi: 10.1038/embor.2011.65 PMID: 21566644

45. Qiu X, Brown K, Hirschey MD, Verdin E and Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010; 12: 662–667. doi: 10.1016/j.cmet.2010.11.015 PMID: 21109198

46. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulatory mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol. 2008; 382: 790–801. doi: 10.1016/j.jmb.2008.07.048 PMID: 18680753

47. Sometani S, Yagi Y, Ono M, Tanioka Y, Matsumoto M, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010; 143: 893–902. doi: 10.1016/j.cell.2010.10.002 PMID: 21094524

48. Tao R, Coley MJ, Pennington JD, Ozden O, Park SH, Jiang H, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010; 40: 893–904. doi: 10.1016/j.molcel.2010.12.013 PMID: 21172655

49. Goncharov NV, Avdonin PV, Nadeev AD, Zharkikh IL, Jenkins RO. Reactive oxygen species in pathogenesis of atherosclerosis. Curr Pharm Des. 2015; 21: 1134–46. PMID: 25312724

50. Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014; 237: 208–19. doi: 10.1016/j.atherosclerosis.2014.09.001 PMID: 25244505

51. Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med. 2013; 63: 222–34. doi: 10.1016/j.freeradbiomed.2013.05.002 PMID: 23665396

52. Xue L, Xu F, Meng L, Wei S, Wang J, Hao P, et al. Acetylation-dependent regulation of mitochondrial ALDH2 activation by SIRT3 mediates acute ethanol-induced eNOS activation. FEBS Lett. 2012; 586: 137–42. doi: 10.1016/j.febslet.2011.11.031 PMID: 22155639
54. Samant SA, Zhang HJ, Hong Z, Pillai VB, Sundaresan NR, Wolfgeher D, et al. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol. 2014; 34: 807–19. doi: 10.1128/MCB.01483-13 PMID: 24344202

55. Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res. 2014; 103: 485–97. doi: 10.1093/cvr/cvu156 PMID: 24966184

56. Lu Z, Chen Y, Aponte AM, Battaglia V, Gucek M, Sack MN. Prolonged fasting identifies heat shock protein 10 as a Sirtuin 3 substrate: elucidating a new mechanism linking mitochondrial protein acetylation to fatty acid oxidation enzyme folding and function. J Biol Chem. 2015; 290: 2466–76. doi: 10.1074/jbc.M114.606228 PMID: 25505263

57. Zhang B, Cui S, Bai X, Zhuo L, Sun X, Hong Q, et al. SIRT3 overexpression antagonizes high glucose accelerated cellular senescence in human diploid fibroblasts via the SIRT3-FOXO1 signaling pathway. Age (Dordr). 2013; 35: 2237–53.

58. Zhang Y, Bharathi SS, Rardin MJ, Uppala R, Verdin E, Gibson BW, et al. SIRT3 and SIRT5 regulate the enzyme activity and cardiolipin binding of very long-chain acyl-CoA dehydrogenase. PLoS One. 2015; 10: e0122297. doi: 10.1371/journal.pone.0122297 PMID: 25811481